Weycker D, et al. - In this retrospective cohort study, researchers used data from two US private healthcare claims repositories (01/2010–12/2016) to determine the incidence, clinical results, and economic costs of chemotherapy-induced thrombocytopenia (CIT) in current US clinical practice. They analyzed data from adults who received selected myelosuppressive chemotherapy regimens for solid tumors or non-Hodgkin’s lymphoma. They assessed CIT incidence during the chemotherapy course (max. no. cycles = 8). During the cycle of the CIT episode, evaluation of related consequences and costs (2016US$) was carried out. Findings revealed a high CIT incidence was reported, specifically among patients receiving gemcitabine-based regimens. They also reported substantial costs of CIT-related care, mean cost was $2179 (2029-2329) across cycles with CIT. Substantial clinical and economic benefits could be seen with interventions meant to identify and target high-risk patients for preventative measures.